{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:49:23Z","timestamp":1792172963421,"version":"4.4.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":304,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1111\/jth.15270","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T02:52:04Z","timestamp":1613530324000},"page":"1436-1446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"title":["Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran\u2014Results of the phase 1 inhibitor cohort"],"prefix":"10.1016","volume":"19","author":[{"given":"K. John","family":"Pasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshko","family":"Lissitchkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasily","family":"Mamonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Mant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Timofeeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Bagot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratima","family":"Chowdary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pencho","family":"Georgiev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana","family":"Gercheva\u2010Kyuchukova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Madigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huy","family":"Van Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baisong","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig C.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret V.","family":"Ragni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.15270_bb0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1161\/01.ATV.0000193624.28251.83","article-title":"What does it take to make the perfect clot?","volume":"26","author":"Monroe","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/jth.15270_bb0015","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","article-title":"Haemophilias A and B","volume":"361","author":"Bolton\u2010Maggs","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/jth.15270_bb0020","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"issue":"Suppl 4","key":"10.1111\/jth.15270_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2516.2007.01552.x","article-title":"Optimizing outcomes for patients with severe haemophilia a","volume":"13","author":"Pipe","year":"2007","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15270_bb0030","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/bjh.13365","article-title":"The current status of prophylactic replacement therapy in children and adults with haemophilia","volume":"169","author":"Ljung","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15270_bb0035","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15270_bb0040","first-page":"S112","article-title":"Current challenges in the management of hemophilia","volume":"21","author":"Bauer","year":"2015","journal-title":"Am J Manag Care"},{"issue":"Suppl 4","key":"10.1111\/jth.15270_bb0045","first-page":"s77","article-title":"Present and future challenges in the treatment of haemophilia: a clinician's perspective","volume":"11","author":"Mannucci","year":"2013","journal-title":"Blood Transfus"},{"key":"10.1111\/jth.15270_bb0050","unstructured":"World Federation of Hemophilia. Treatment safety and supply. 2020. Available from: https:\/\/www.wfh.org\/en\/our\u2010work\u2010treatment\/treatment\u2010safety\u2010supply. Last accessed 4 Mar 2020."},{"key":"10.1111\/jth.15270_bb0055","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1365-2516.2007.01518.x","article-title":"European study on orthopaedic status of haemophilia patients with inhibitors","volume":"13","author":"Morfini","year":"2007","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15270_bb0060","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13023-018-0929-9","article-title":"Inhibitor clinical burden of disease: a comparative analysis of the CHESS data","volume":"13","author":"Oladapo","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1111\/jth.15270_bb0065","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-0609.2012.01754.x","article-title":"Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice","volume":"88","author":"Benson","year":"2012","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1111\/jth.15270_bb0070","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bjh.12091","article-title":"Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia (4th edition)","volume":"160","author":"Collins","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15270_bb0075","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood-2014-05-577643","article-title":"Toward optimal therapy for inhibitors in hemophilia","volume":"124","author":"Kempton","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.15270_bb0080","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2516.2006.01403.x","article-title":"Current use of by\u2010passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors","volume":"13","author":"Astermark","year":"2007","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15270_bb0085","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2362.2009.02168.x","article-title":"Thrombin generation in haemophilia a patients with factor VIII inhibitors after infusion of recombinant factor VIIIa","volume":"39","author":"Eichinger","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1111\/jth.15270_bb0090","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/jth.12958","article-title":"Hemophilia B: molecular pathogenesis and mutation analysis","volume":"13","author":"Goodeve","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15270_bb0095","first-page":"582","article-title":"Recurrent episodes of anaphylaxis in a patient with haemophilia B: a case report","volume":"14","author":"Mauro","year":"2016","journal-title":"Blood Transfus"},{"key":"10.1111\/jth.15270_bb0100","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti\u2010TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15270_bb0105","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/ajh.24543","article-title":"2017 Clinical trials update: innovations in hemophilia therapy","volume":"91","author":"Hartmann","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.15270_bb0110","doi-asserted-by":"crossref","first-page":"5514","DOI":"10.1182\/blood-2010-10-311936","article-title":"Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor","volume":"117","author":"Waters","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.15270_bb0115","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.thromres.2012.08.299","article-title":"Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia","volume":"130","author":"Gissel","year":"2012","journal-title":"Thromb Res"},{"key":"10.1111\/jth.15270_bb0120","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/blood-2016-05-718635","article-title":"Design and characterization of an APC\u2010specific serpin for the treatment of hemophilia","volume":"129","author":"Polderdijk","year":"2017","journal-title":"Blood"},{"key":"10.1111\/jth.15270_bb0125","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat Med"},{"key":"10.1111\/jth.15270_bb0130","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII\u2010mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15270_bb0135","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15270_bb0140","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.15270_bb0145","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of antithrombin in hemophilia A or B with RNAi therapy","volume":"377","author":"Pasi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15270_bb0150","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"key":"10.1111\/jth.15270_bb0155","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/bja\/88.6.848","article-title":"Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies","volume":"88","author":"Walker","year":"2002","journal-title":"Br J Anaesth"},{"key":"10.1111\/jth.15270_bb0160","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1111\/jth.15270_bb0165","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2013a new facility for the measurement of health\u2010related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"key":"10.1111\/jth.15270_bb0170","first-page":"115","article-title":"Validation of the haemophilia\u2010specific quality of life questionnaire for adult patients with haemophilia (HAEM\u2010A\u2010QOL)","volume":"90","author":"von Mackensen","year":"2005","journal-title":"Haematologica"},{"key":"10.1111\/jth.15270_bb0175","doi-asserted-by":"crossref","first-page":"s104","DOI":"10.7861\/clinmedicine.16-6-s104","article-title":"Drug\u2010induced liver injury","volume":"16","author":"Katarey","year":"2016","journal-title":"Clin Med (Lond)"},{"key":"10.1111\/jth.15270_bb0180","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/hae.12642","article-title":"Interpreting important health\u2010related quality of life change using the Haem\u2010a\u2010QoL","volume":"21","author":"Wyrwich","year":"2015","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15270_bb0185","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/jth.13960","article-title":"Mild antithrombin deficiency and risk of recurrent venous thromboembolism: results from the mega follow\u2010up study","volume":"16","author":"Sokol","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15270_bb0190","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.3324\/haematol.2018.210666","article-title":"Incidence and features of thrombosis in children with inherited antithrombin deficiency","volume":"104","author":"de la Morena\u2010Barrio","year":"2019","journal-title":"Haematologica"},{"key":"10.1111\/jth.15270_bb0195","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1055\/s-0037-1615679","article-title":"Symptomatic onset of severe hemophilia a in childhood is dependent on the presence of prothrombotic risk factors","volume":"85","author":"Escuriola Ettingshausen","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.15270_bb0200","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2141.2007.06693.x","article-title":"Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients","volume":"138","author":"Shetty","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15270_bb0205","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/labmed\/lmw001","article-title":"Widely used types and clinical applications of D\u2010dimer assay","volume":"47","author":"Riley","year":"2016","journal-title":"Lab Med"},{"key":"10.1111\/jth.15270_bb0210","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.V94.7.2169.419k22_2169_2178","article-title":"\"Normal\" thrombin generation","volume":"94","author":"Butenas","year":"1999","journal-title":"Blood"},{"key":"10.1111\/jth.15270_bb0215","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1160\/TH09-03-0180","article-title":"Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogram","volume":"102","author":"Machlus","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.15270_bb0220","unstructured":"FDA. Feiba US prescribing information. Available from: https:\/\/www.fda.gov\/media\/78852\/download. Last accessed 4 Mar 2020."},{"key":"10.1111\/jth.15270_bb0225","unstructured":"Qian K, Huang S, Akinc A, Liu J. Thrombin generation response with the addition of bypassing agents in plasma of patients treated with fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia. WFH 2018 World Congress. 2018;M\u2010P\u2010219 (141)."},{"key":"10.1111\/jth.15270_bb0230","unstructured":"Nordisk N. US prescribing information: Novoseven\u00ae, coagulation factor VIIa (recombinant), for intravenous use only. 2006. Available from: https:\/\/www.fda.gov\/media\/70435\/download. Last accessed 27 August 2020."},{"key":"10.1111\/jth.15270_bb0235","unstructured":"Sanofi. An open\u2010label extension study of an investigational drug, fitusiran, in patients with moderate or severe hemophilia a or b. ClinicalTrials.gov NCT02554773, 2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02554773. Last accessed 27 August 2020."},{"key":"10.1111\/jth.15270_bb0240","unstructured":"Sanofi. A study of fitusiran (ALN\u2010AT3SC) in severe hemophilia a and b patients with inhibitors (ATLAS\u2010INH). ClinicalTrials.gov NCT03417102, 2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03417102. Last accessed 27 August 2020."},{"key":"10.1111\/jth.15270_bb0245","unstructured":"Sanofi. A study of fitusiran (ALN\u2010AT3SC) in severe hemophilia a and b patients without inhibitors. ClinicalTrials.gov NCT03417245, 2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03417245. Last accessed 27 August 2020."},{"key":"10.1111\/jth.15270_bb0250","unstructured":"Sanofi. A study of fitusiran in severe hemophilia a and b patients previously receiving factor or bypassing agent prophylaxis (ATLAS\u2010PPX). ClinicalTrials.gov NCT03549871, 2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03549871. Last accessed 27 August 2020."},{"key":"10.1111\/jth.15270_bb0255","unstructured":"Sanofi. Fitusiran prophylaxis in male pediatric subjects aged 1 to less than 12 years with hemophilia a or b (ATLAS\u2010PEDS). ClinicalTrials.gov NCT03974113, 2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03974113. Last accessed 27 August 2020."},{"key":"10.1111\/jth.15270_bb0260","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.blre.2010.10.001","article-title":"Venous access in the management of hemophilia","volume":"25","author":"Valentino","year":"2011","journal-title":"Blood Rev"},{"issue":"Suppl 3","key":"10.1111\/jth.15270_bb0265","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1365-2516.2008.01736.x","article-title":"Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors","volume":"14","author":"Fischer","year":"2008","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15270_bb0270","series-title":"Evaluation of room temperature and accelerated stability data for fitusiran, an investigational RNAi therapeutic targeting antithrombin for treatment of hemophilia and rare bleeding disorders","author":"McKinney","year":"2017"},{"issue":"3","key":"10.1111\/jth.15270_bb0275","doi-asserted-by":"crossref","first-page":"A38","DOI":"10.1016\/j.jval.2013.03.215","article-title":"Placebo effect sizes for patient reported outcomes in well\u2010controlled drug trials: a 12\u2010year systematic review","volume":"16","author":"Frendl","year":"2013","journal-title":"Value Health"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15270","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.15270","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622007760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622007760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15270","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:32:28Z","timestamp":1761535948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622007760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1538783622007760"],"URL":"https:\/\/doi.org\/10.1111\/jth.15270","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran\u2014Results of the phase 1 inhibitor cohort","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.15270","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 Sanofi. Journal of Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}